8-K: Astria Stockholders Approve BioCryst Merger

Astria Therapeutics stockholders have approved the acquisition by BioCryst Pharmaceuticals, with the merger expected to close around January 23, 2026.

Summary

• Astria Therapeutics, Inc. held a special meeting of stockholders on January 21, 2026, at which a quorum was present with 35,757,073 shares, representing approximately 62.64% of the voting power.
• Stockholders approved the Merger Proposal, which involved the acquisition of Astria by BioCryst Pharmaceuticals, Inc., with 35,673,135 votes for, 12,977 against, and 70,961 abstaining.
• The Merger Proposal required the affirmative vote of holders of not less than a majority of the 57,084,838 outstanding shares of Astria Common Stock as of the December 9, 2025 record date.
• Stockholders also approved, on a non-binding, advisory basis, the Merger-related named executive officer compensation with 33,236,762 votes for, 2,035,104 against, and 485,206 abstaining.
• The proposal to approve one or more adjournments of the Special Meeting was rendered moot and not called for a vote because the Merger Proposal was approved.
• Astria issued a press release on January 21, 2026, announcing the approval of the Merger Proposal.
• The merger is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.

Sentiment

Score: 8

Explanation: The overwhelming approval of the merger by stockholders and the expected swift closing date indicate a highly positive outcome for the company and its shareholders, despite standard cautionary language regarding closing conditions and risks.

Positives

• Stockholders overwhelmingly approved the Merger Proposal, indicating strong support for the acquisition by BioCryst Pharmaceuticals.
• The non-binding advisory vote on executive compensation also passed with a significant majority, suggesting alignment with stockholder interests.
• A quorum was successfully established with approximately 62.64% of voting power represented, demonstrating active stockholder engagement.
• The merger is expected to close quickly, on or about January 23, 2026, providing a clear timeline for the transaction's completion.

Negatives

• A small number of stockholders voted against the Merger Proposal (12,977 votes) and the Compensation Proposal (2,035,104 votes).

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the right of one or both parties to terminate the merger agreement.
• The outcome of any legal proceedings that may be instituted against BioCryst or Astria.
• Failure to satisfy any of the conditions to the Merger on a timely basis or at all.

Future Outlook

The merger between Astria Therapeutics and BioCryst Pharmaceuticals is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. The company cautions that forward-looking statements are subject to risks, including potential termination of the merger agreement, legal proceedings, and failure to meet closing conditions.

Management Comments

• Astria Therapeutics, Inc. announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc.

Industry Context

This acquisition represents a consolidation within the biopharmaceutical sector, specifically impacting companies focused on allergic and immunologic diseases. Astria's pipeline, including navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis, will now be integrated into BioCryst's portfolio, potentially enhancing BioCryst's market position in these therapeutic areas.

Stakeholder Impact

• Shareholders: Astria shareholders will receive consideration from BioCryst as per the merger agreement, with the approval signifying their consent to this transaction.
• Employees: Integration into BioCryst may lead to changes in roles or organizational structure as the companies combine operations.
• Patients: Astria's therapeutic programs (navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis) will continue development under BioCryst, potentially impacting future treatment availability and access.

Next Steps

• Closing of the Merger on or about January 23, 2026, subject to customary closing conditions.

Key Dates

Keywords

Astria Therapeutics, BioCryst Pharmaceuticals, Merger, Acquisition, Stockholder Vote, 8-K Filing, Biopharmaceutical, Hereditary Angioedema, Atopic Dermatitis, Nasdaq ATXS